Mind and body: How the health of the body impacts on neuropsychiatry

Frontiers in Pharmacology

Volumn 4 DEC, Issue , 2013, Pages

  Renoir, Thibault ^a   Hasebe, Kyoko ^b   Gray, Laura ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b DEAKIN UNIVERSITY   (Australia)

Author keywords

HPA axis; Inflammatory processes; Mind body interactions; Mood disorders; Peripheral disorders; Psychiatric diseases; Stress response

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANTIDEPRESSANT AGENT; C 108297; CELECOXIB; CORTICOSTEROID; CORTICOSTERONE; ETANERCEPT; FLUOXETINE; GLUCOCORTICOID; HORMONE RECEPTOR STIMULATING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; INTERLEUKIN 2; MIFEPRISTONE; MINOCYCLINE; OMEGA 3 FATTY ACID; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UBIDECARENONE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIDEPRESSANT ACTIVITY; BIPOLAR DISORDER; DEPRESSION; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; GENETIC POLYMORPHISM; HEALTH STATUS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE DYSREGULATION; IMMUNOMODULATION; INFLAMMATION; MAJOR DEPRESSION; MANIA; MENTAL DISEASE; MENTAL STRESS; METABOLIC DISORDER; NEUROPSYCHIATRY; NONHUMAN; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SCHIZOPHRENIA; SYSTEMIC DISEASE;

EID: 84891689803     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00158     Document Type: Review

References (233)

1. Abbasi, S. H., Hosseini, F., Modabbernia, A., Ashrafi, M., and Akhondzadeh, S. (2012). Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J. Affect. Disord. 141, 308-314. doi: 10.1016/j.jad.2012.03.033.
2. Adzic, M., Djordjevic, J., Djordjevic, A., Niciforovic, A., Demonacos, C., Radojcic, M., et al. (2009). Acute or chronic stress induce cell compartment-specific phosphorylation of glucocorticoid receptor and alter its transcriptional activity in Wistar rat brain. J. Endocrinol. 202, 87-97. doi: 10.1677/joe-08-0509.
3. Ago, Y., Arikawa, S., Yata, M., Yano, K., Abe, M., Takuma, K., et al. (2008). Antidepressant-like effects of the glucocorticoid receptor antagonist RU-43044 are associated with changes in prefrontal dopamine in mouse models of depression. Neuropharmacology 55, 1355-1363. doi: 10.1016/j.neuropharm.2008.08.026.
4. Aid, S., Langenbach, R., and Bosetti, F. (2008). Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2. J. Neuroinflammation 5, 17. doi: 10.1186/1742-2094-5-17.
5. Akhondzadeh, S., Jafari, S., Raisi, F., Nasehi, A. A., Ghoreishi, A., Salehi, B., et al. (2009). Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress. Anxiety 26, 607-611. doi: 10.1002/da.20589.
6. Alavi, M., Grebely, J., Matthews, G. V., Petoumenos, K., Yeung, B., Day, C., et al. (2012). Effect of pegylated interferon-alpha-2a treatment on mental health during recent hepatitis C virus infection. J. Gastroenterol. Hepatol. 27, 957-965. doi: 10.1111/j.1440-1746.2011.07035.x.
7. Almeida, O. P., Flicker, L., Yeap, B. B., Alfonso, H., McCaul, K., and Hankey, G. J. (2012). Aspirin decreases the risk of depression in older men with high plasma homocysteine. Transl. Psychiatry 2:e151. doi: 10.1038/tp.2012.79.
8. Anagnostis, P., Athyros, V. G., Tziomalos, K., Karagiannis, A., and Mikhailidis, D. P. (2009). The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J. Clin. Endocrinol. Metab. 94, 2692-2701. doi: 10.1210/jc.2009-0370.
9. Ananthakrishnan, A. N., Gainer, V. S., Cai, T., Perez, R. G., Cheng, S. C., Savova, G., et al. (2013a). Similar risk of depression and anxiety following surgery or hospitalization for Crohn's disease and ulcerative colitis. Am. J. Gastroenterol. 108, 594-601. doi: 10.1038/ajg.2012.471.
10. Ananthakrishnan, A. N., Khalili, H., Pan, A., Higuchi, L. M., de Silva, P., Richter, J. M., et al. (2013b). Association between depressive symptoms and incidence of Crohn's disease and ulcerative colitis: results from the Nurses' Health Study. Clin. Gastroenterol. Hepatol. 11, 57-62. doi: 10.1016/j.cgh.2012.08.032.
11. Anderson, R. J., Freedland, K. E., Clouse, R. E., and Lustman, P. J. (2001). The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 24, 1069-1078. doi: 10.2337/diacare.24.6.1069.
12. Anglin, R. E., Rosebush, P. I., and Mazurek, M. F. (2006). The neuropsychiatric profile of Addison's disease: revisiting a forgotten phenomenon. J. Neuropsychiatry Clin. Neurosci. 18, 450-459. doi: 10.1176/appi.neuropsych.18.4.450.
13. Appel, K., Schwahn, C., Mahler, J., Schulz, A., Spitzer, C., Fenske, K., et al. (2011). Moderation of adult depression by a polymorphism in the FKBP5 gene and childhood physical abuse in the general population. Neuropsychopharmacology 36, 1982-1991. doi: 10.1038/npp.2011.81.
14. Arzt, E., Kovalovsky, D., Igaz, L. M., Costas, M., Plazas, P., Refojo, D., et al. (2000). Functional cross-talk among cytokines, T-cell receptor, and glucocorticoid receptor transcriptional activity and action. Ann. N.Y. Acad. Sci. 917, 672-677. doi: 10.1111/j.1749-6632.2000.tb05433.x.
15. Assies, J., Pouwer, F., Lok, A., Mocking, R. J., Bockting, C. L., Visser, I., et al. (2010). Plasma and erythrocyte fatty acid patterns in patients with recurrent depression: a matched case-control study. PLoS ONE 5:e10635. doi: 10.1371/journal.pone.0010635.
16. Atzeni, F., Sarzi-Puttini, P., Botsios, C., Carletto, A., Cipriani, P., Favalli, E. G., et al. (2012). Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun. Rev. 12, 225-229. doi: 10.1016/j.autrev.2012.06.008.
17. Azzawi, M., and Hasleton, P. (1999). Tumour necrosis factor alpha and the cardiovascular system: its role in cardiac allograft rejection and heart disease. Cardiovasc. Res. 43, 850-859. doi: 10.1016/S0008-6363(99)00138-8.
18. Bangasser, D. A., and Valentino, R. J. (2012). Sex differences in molecular and cellular substrates of stress. Cell. Mol. Neurobiol. 32, 709-723. doi: 10.1007/s10571-012-9824-4.
19. Barnes, P. J. (2006). How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br. J. Pharmacol. 148, 245-254. doi: 10.1038/sj.bjp.0706736.
20. Barnum, C. J., Pace, T. W., Hu, F., Neigh, G. N., and Tansey, M. G. (2012). Psychological stress in adolescent and adult mice increases neuroinflammation and attenuates the response to LPS challenge. J. Neuroinflammation 9, 9. doi: 10.1186/1742-2094-9-9.
21. Barth, J., Schumacher, M., and Herrmann-Lingen, C. (2004). Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom. Med. 66, 802-813. doi: 10.1097/01.psy.0000146332.53619.b2.
22. Bekker, M. H., and van Mens-Verhulst, J. (2007). Anxiety disorders: sex differences in prevalence, degree, and background, but gender-neutral treatment. Gend. Med. 4(Suppl. B), S178-S193. doi: 10.1016/S1550-8579(07)80057-X.
23. Berry, A., Bellisario, V., Capoccia, S., Tirassa, P., Calza, A., Alleva, E., et al. (2012). Social deprivation stress is a triggering factor for the emergence of anxiety-and depression-like behaviours and leads to reduced brain BDNF levels in C57BL/6J mice. Psychoneuroendocrinology 37, 762-772. doi: 10.1016/j.psyneuen.2011.09.007.
24. Birerdinc, A., Afendy, A., Stepanova, M., Younossi, I., Baranova, A., and Younossi, Z. M. (2012). Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C). Brain Behav. 2, 525-531. doi: 10.1002/brb3.72.
25. Bloch, M. H., and Hannestad, J. (2012). Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol. Psychiatry 17, 1272-1282. doi: 10.1038/mp.2011.100.
26. Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., and Montori, V. (2006). Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275-2285. doi: 10.1001/jama.295.19.2275.
27. Bonilla-Jaime, H., Retana-Marquez, S., Arteaga-Silva, M., Hernandez-Gonzalez, M., and Vazquez-Palacios, G. (2010). Circadian activity of corticosterone in an animal model of depression: response to muscarinic cholinergic stimulation. Physiol. Behav. 100, 311-315. doi: 10.1016/j.physbeh.2010.03.002.
28. Bradley, R. G., Binder, E. B., Epstein, M. P., Tang, Y., Nair, H. P., Liu, W., et al. (2008). Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch. Gen. Psychiatry 65, 190-200. doi: 10.1001/archgenpsychiatry.2007.26.
29. Branco-de-Almeida, L. S., Kajiya, M., Cardoso, C. R., Silva, M. J., Ohta, K., Rosalen, P. L., et al. (2011). Selective serotonin reuptake inhibitors attenuate the antigen presentation from dendritic cells to effector T lymphocytes. FEMS Immunol. Med. Microbiol. 62, 283-294. doi: 10.1111/j.1574-695X.2011.00816.x.
30. Bremmer, M. A., Deeg, D. J., Beekman, A. T., Penninx, B. W., Lips, P., and Hoogendijk, W. J. (2007). Major depression in late life is associated with both hypo-and hypercortisolemia. Biol. Psychiatry 62, 479-486. doi: 10.1016/j.biopsych.2006.11.033.
31. Brenner, R. R., Ayala, S., and Garda, H. A. (2001). Effect of dexamethasone on the fatty acid composition of total liver microsomal lipids and phosphatidylcholine molecular species. Lipids 36, 1337-1345. doi: 10.1007/s11745-001-0850-1.
32. Brunello, N., Alboni, S., Capone, G., Benatti, C., Blom, J. M., Tascedda, F., et al. (2006). Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression. Int. Clin. Psychopharmacol. 21, 219-225. doi: 10.1097/00004850-200607000-00004.
33. Bush, D. E., Ziegelstein, R. C., Patel, U. V., Thombs, B. D., Ford, D. E., Fauerbach, J. A., et al. (2005). Post-myocardial infarction depression. Evidence Report/Technology Assessment 123, 1-8.
34. Capuron, L., Neurauter, G., Musselman, D. L., Lawson, D. H., Nemeroff, C. B., Fuchs, D., et al. (2003). Interferon-alpha-induced changes in tryptophan metabolism: relationship to depression and paroxetine treatment. Biol. Psychiatry 54, 906-914. doi: 10.1016/S0006-322300173-2.
35. Capuron, L., Ravaud, A., and Dantzer, R. (2000). Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J. Clin. Oncol. 18, 2143-2151.
36. Capuron, L., Ravaud, A., Gualde, N., Bosmans, E., Dantzer, R., Maes, M., et al. (2001). Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 26, 797-808. doi: 10.1016/S0306-4530(01)00030-0.
37. Capuron, L., Ravaud, A., Miller, A. H., and Dantzer, R. (2004). Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav. Immun. 18, 205-213. doi: 10.1016/j.bbi.2003.11.004.
38. Capuron, L., Ravaud, A., Neveu, P. J., Miller, A. H., Maes, M., and Dantzer, R. (2002). Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol. Psychiatry 7, 468-473. doi: 10.1038/sj.mp.4000995.
39. Carnethon, M. R., Kinder, L. S., Fair, J. M., Stafford, R. S., and Fortmann, S. P. (2003). Symptoms of depression as a risk factor for incident diabetes: findings from the national health and nutrition examination epidemiologic follow-up study, 1971-1992. Am. J. Epidemiol. 158, 416-423. doi: 10.1093/aje/kwg172.
40. Carney, R. M., and Freedland, K. E. (2008). Depression in patients with coronary heart disease. Am. J. Med. 121, S20-S27. doi: 10.1016/j.amjmed.2008.09.010.
41. Carney, R. M., Freedland, K. E., Rich, M. W., Smith, L. J., and Jaffe, A. S. (1993). Ventricular tachycardia and psychiatric depression in patients with coronary artery disease. Am. J. Med. 95, 23-28. doi: 10.1016/0002-9343(93)90228-H.
42. Carney, R. M., Freedland, K. E., Stein, P. K., Skala, J. A., Hoffman, P., and Jaffe, A. S. (2000). Change in heart rate and heart rate variability during treatment for depression in patients with coronary heart disease. Psychosom. Med. 62, 639-647.
43. Caspi, A., Sugden, K., Moffitt, T. E., Taylor, A., Craig, I. W., Harrington, H., et al. (2003). Influence of life stress on depression: moderation by a polymorphism in the 5-HTT Gene. Science 301, 386-389. doi: 10.1126/science.1083968.
44. Champaneri, S., Wand, G. S., Malhotra, S. S., Casagrande, S. S., and Golden, S. H. (2010). Biological basis of depression in adults with diabetes. Curr. Diab. Rep. 10, 396-405. doi: 10.1007/s11892-010-0148-9.
45. Chan, O., Inouye, K., Riddell, M. C., Vranic, M., and Matthews, S. G. (2003). Diabetes and the hypothalamo-pituitary-adrenal (HPA) axis. Minerva Endocrinol. 28, 87-102.
46. Chantong, B., Kratschmar, D. V., Nashev, L. G., Balazs, Z., and Odermatt, A. (2012). Mineralocorticoid and glucocorticoid receptors differentially regulate NF-kappaB activity and pro-inflammatory cytokine production in murine BV-2 microglial cells. J. Neuroinflammation 9, 260. doi: 10.1186/1742-2094-9-260.
47. Chen, H. F., and Su, H. M. (2013). Exposure to a maternal n-3 fatty acid-deficient diet during brain development provokes excessive hypothalamic-pituitary-adrenal axis responses to stress and behavioral indices of depression and anxiety in male rat offspring later in life. J. Nutr. Biochem. 24, 70-80. doi: 10.1016/j.jnutbio.2012.02.006.
48. Christiansen, S., Bouzinova, E. V., Palme, R., and Wiborg, O. (2012). Circadian activity of the hypothalamic-pituitary-adrenal axis is differentially affected in the rat chronic mild stress model of depression. Stress (Amsterdam, Netherlands) 15, 647-657. doi: 10.3109/10253890.2011.654370.
49. Clark, J. A., Flick, R. B., Pai, L. Y., Szalayova, I., Key, S., Conley, R. K., et al. (2007). Glucocorticoid modulation of tryptophan hydroxylase-2 protein in raphe nuclei and 5-hydroxytryptophan concentrations in frontal cortex of C57/Bl6 mice. Mol. Psychiatry 13, 498-506. doi: 10.1038/sj.mp.4002041.
50. Clark, J. A., Pai, L.-Y., Flick, R. B., and Rohrer, S. P. (2005). Differential hormonal regulation of tryptophan hydroxylase-2 mRNA in the murine dorsal raphe nucleus. Biol. Psychiatry 57, 943-946. doi: 10.1016/j.biopsych.2005.01.013.
51. Clouse, R. E., Lustman, P. J., Freedland, K. E., Griffith, L. S., McGill, J. B., and Carney, R. M. (2003). Depression and coronary heart disease in women with diabetes. Psychosom. Med. 65, 376-383. doi: 10.1097/01.PSY.0000041624.96580.1F.
52. Covic, T., Cumming, S. R., Pallant, J. F., Manolios, N., Emery, P., Conaghan, P. G., et al. (2012). Depression and anxiety in patients with rheumatoid arthritis: prevalence rates based on a comparison of the Depression, Anxiety and Stress Scale (DASS) and the hospital, Anxiety and Depression Scale (HADS). BMC Psychiatry 12:6. doi: 10.1186/1471-244x-12-16.
53. Daly, M. (2013). The relationship of C-reactive protein to obesity-related depressive symptoms: a longitudinal study. Obesity (Silver Spring, Md) 21, 248-250. Epub 2013/02/14. doi: 10.1002/oby.20051.
54. Dantzer, R. (2004). Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur. J. Pharmacol. 500, 399-411. doi: 10.1016/j.ejphar.2004.07.040.
55. Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., and Kelley, K. W. (2008). From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9, 46-56. doi: 10.1038/nrn2297.
56. David, D. J., Samuels, B. A., Rainer, Q., Wang, J. W., Marsteller, D., Mendez, I., et al. (2009). Neurogenesis-dependent and-independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 62, 479-493. doi: 10.1016/j.neuron.2009.04.017.
57. Dean, O. M., Data-Franco, J., Giorlando, F., and Berk, M. (2012). Minocycline: therapeutic potential in psychiatry. CNS drugs 26, 391-401. doi: 10.2165/11632000-000000000-00000.
58. de Jonge, P., Roy, J. F., Saz, P., Marcos, G., and Lobo, A. (2006). Prevalent and incident depression in community-dwelling elderly persons with diabetes mellitus: results from the ZARADEMP project. Diabetologia 49, 2627-2633. doi: 10.1007/s00125-006-0442-x.
59. Delarue, J., Matzinger, O., Binnert, C., Schneiter, P., Chioléro, R., and Tappy, L. (2003). Fish oil prevents the adrenal activation elicited by mental stress in healthy men. Diabetes Metab. 29, 289-295. doi: 10.1016/S1262-363670039-3.
60. Dhabhar, F. S. (2009). Enhancing versus suppressive effects of stress on immune function: implications for immunoprotection and immunopathology. Neuroimmunomodulation 16, 300-317. doi: 10.1159/000216188.
61. Diamond, M., Kelly, J. P., and Connor, T. J. (2006). Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur. Neuropsychopharmacol. 16, 481-490. doi: 10.1016/j.euroneuro.2005.11.011.
62. Dickens, C., McGowan, L., Clark-Carter, D., and Creed, F. (2002). Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosom. Med. 64, 52-60.
63. Donner, N. C., Montoya, C. D., Lukkes, J. L., and Lowry, C. A. (2012). Chronic non-invasive corticosterone administration abolishes the diurnal pattern of tph2 expression. Psychoneuroendocrinology 37, 645-661. doi: 10.1016/j.psyneuen.2011.08.008.
64. Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., et al. (2010). A meta-analysis of cytokines in major depression. Biol. Psychiatry 67, 446-457. doi: 10.1016/j.biopsych.2009.09.033.
65. Dringen, R. (2005). Oxidative and antioxidative potential of brain microglial cells. Antioxid. Redox Signal. 7, 1223-1233. doi: 10.1089/ars.2005.7.1223.
66. Dunn, A. J. (2000). Cytokine activation of the HPA axis. Ann. N.Y. Acad. Sci. 917, 608-617. doi: 10.1111/j.1749-6632.2000.tb05426.x.
67. Dyer, A. R., Persky, V., Stamler, J., Paul, O., Shekelle, R. B., Berkson, D. M., et al. (1980). Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am. J. Epidemiol. 112, 736-749.
68. Eller, T., Vasar, V., Shlik, J., and Maron, E. (2009). The role of IL-2 and soluble IL-2R in depression and antidepressant response. Curr. Opin. Invest. Drugs (London, England: 2000) 10, 638-643.
69. Ellsworth, K. A., Moon, I., Eckloff, B. W., Fridley, B. L., Jenkins, G. D., Batzler, A., et al. (2013). FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder. Pharmacogenet. Genomics 23, 156-166. doi: 10.1097/FPC.0b013e32835dc133.
70. Ertenli, I., Ozer, S., Kiraz, S., Apras, S. B., Akdogan, A., Karadag, O., et al. (2012). Infliximab, a TNF-alpha antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level. Rheumatol. Int. 32, 323-330. doi: 10.1007/s00296-010-1616-x.
71. Evans, J., Sun, Y., McGregor, A., and Connor, B. (2012). Allopregnanolone regulates neurogenesis and depressive/anxiety-like behaviour in a social isolation rodent model of chronic stress. Neuropharmacology 63, 1315-1326. doi: 10.1016/j.neuropharm.2012.08.012.
72. Fardet, L., Petersen, I., and Nazareth, I. (2012). Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care. Am. J. Psychiatry 169, 491-497. doi: 10.1176/appi.ajp.2011.11071009.
73. Farooq, R. K., Isingrini, E., Tanti, A., Le Guisquet, A.-M., Arlicot, N., Minier, F., et al. (2012). Is unpredictable chronic mild stress (UCMS) a reliable model to study depression-induced neuroinflammation. Behav. Brain Res. 231, 130-137. doi: 10.1016/j.bbr.2012.03.020.
74. Feng, L., Tan, C. H., Merchant, R. A., and Ng, T. P. (2008). Association between depressive symptoms and use of HMG-CoA reductase inhibitors (statins), corticosteroids and histamine H(2) receptor antagonists in community-dwelling older persons: cross-sectional analysis of a population-based cohort. Drugs Aging 25, 795-805. doi: 10.2165/00002512-200825090-00005.
75. Fields, C., Drye, L., Vaidya, V., and Lyketsos, C. (2012). Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: findings from a randomized controlled trial. Am. J. Geriatric Psychiatry 20, 505-513. doi: 10.1097/JGP.0b013e318227f4da.
76. Forbes, L. M., and Chaney, R. H. (1980). Cardiovascular changes during acute depression. Psychosomatics 21, 472-477. doi: 10.1016/S0033-318273657-5.
77. Forester, B. P., Zuo, C. S., Ravichandran, C., Harper, D. G., Du, F., Kim, S., et al. (2012). Coenzyme Q10 effects on creatine kinase activity and mood in geriatric bipolar depression. J. Geriatric Psychiatry Neurology 25, 43-50. doi: 10.1177/0891988712436688.
78. Francis, J., Weiss, R. M., Johnson, A. K., and Felder, R. B. (2003). Central mineralocorticoid receptor blockade decreases plasma TNF-alpha after coronary artery ligation in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284, R328-R335. doi: 10.1152/ajpregu.00376.2002.
79. Frank, M. G., Thompson, B. M., Watkins, L. R., and Maier, S. F. (2012). Glucocorticoids mediate stress-induced priming of microglial pro-inflammatory responses. Brain Behav. Immun. 26, 337-345. doi: 10.1016/j.bbi.2011.10.005.
80. Frank, M. G., Watkins, L. R., and Maier, S. F. (2011). Stress-and glucocorticoid-induced priming of neuroinflammatory responses: potential mechanisms of stress-induced vulnerability to drugs of abuse. Brain Behav. Immun. 25(Suppl. 1), S21-S28. doi: 10.1016/j.bbi.2011.01.005.
81. Gallagher, P., Watson, S., Smith, M. S., Ferrier, I. N., and Young, A. H. (2005). Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia. Biol. Psychiatry 57, 155-161. doi: 10.1016/j.biopsych.2004.10.017.
82. Gilbert, K., Arseneault-Breard, J., Flores Monaco, F., Beaudoin, A., Bah, T. M., Tompkins, T. A., et al. (2013). Attenuation of post-myocardial infarction depression in rats by n-3 fatty acids or probiotics starting after the onset of reperfusion. Br. J. Nutr. 109, 50-56. doi: 10.1017/S0007114512003807.
83. Godha, D., Shi, L., and Mavronicolas, H. (2010). Association between tendency towards depression and severity of rheumatoid arthritis from a national representative sample: the Medical Expenditure Panel Survey. Curr. Med. Res. Opin. 26, 1685-1690. doi: 10.1185/03007991003795808.
84. Goleva, E., Li, L. B., and Leung, D. Y. (2009). IFN-gamma reverses IL-2-and IL-4-mediated T-cell steroid resistance. Am. J. Resp. Cell Mol. Biol. 40, 223-230. doi: 10.1165/rcmb.2007-0327OC.
85. González, H. M., and Tarraf, W. (2013). Comorbid cardiovascular disease and major depression among ethnic and racial groups in the United States. Int. Psychogeriatrics 25, 833-841. doi: 10.1017/S1041610212002062.
86. Gourley, S. L., Wu, F. J., and Taylor, J. R. (2008). Corticosterone regulates pERK1/2 map kinase in a chronic depression model. Ann. N.Y. Acad. Sci. 1148, 509-514. doi: 10.1196/annals.1410.076.
87. Guillemin, G. J., Smythe, G., Takikawa, O., and Brew, B. J. (2005). Expression of indoleamine 2, 3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 49, 15-23. doi: 10.1002/glia.20090.
88. Halder, I., Marsland, A. L., Cheong, J., Muldoon, M. F., Ferrell, R. E., and Manuck, S. B. (2010). Polymorphisms in the CRP gene moderate an association between depressive symptoms and circulating levels of C-reactive protein. Brain Behav. Immun. 24, 160-167. doi: 10.1016/j.bbi.2009.09.014.
89. Hannestad, J., DellaGioia, N., and Bloch, M. (2011). The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 36, 2452-2459. doi: 10.1038/npp.2011.132.
90. Hannestad, J., Gallezot, J.-D., Schafbauer, T., Lim, K., Kloczynski, T., Morris, E. D., et al. (2012). Endotoxin-induced systemic inflammation activates microglia: [11C]PBR28 positron emission tomography in nonhuman primates. Neuroimage 63, 232-239. doi: 10.1016/j.neuroimage.2012.06.055.
91. Hariri, A. R., Mattay, V. S., Tessitore, A., Kolachana, B., Fera, F., Goldman, D., et al. (2002). Serotonin transporter genetic variation and the response of the human amygdala. Science 297, 400-403 doi: 10.1126/science.1071829.
92. Hashioka, S., Klegeris, A., Monji, A., Kato, T., Sawada, M., McGeer, P. L., et al. (2007). Antidepressants inhibit interferon-gamma-induced microglial production of IL-6 and nitric oxide. Exp. Neurol. 206, 33-42. doi: 10.1016/j.expneurol.2007.03.022.
93. Hennein, H. A., Ebba, H., Rodriguez, J. L., Merrick, S. H., Keith, F. M., Bronstein, M. H., et al. (1994). Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J. Thorac. Cardiovasc. Surg. 108, 626-635.
94. Henry, C. J., Huang, Y., Wynne, A., Hanke, M., Himler, J., Bailey, M. T., et al. (2008). Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J. Neuroinflammation 5, 15. doi: 10.1186/1742-2094-5-15.
95. Hickman, R. J., Khambaty, T., and Stewart, J. C. (2013). C-reactive protein is elevated in atypical but not nonatypical depression: data from the National Health and Nutrition Examination Survey (NHANES) 1999-2004. J. Behav. Med. doi: 10.1007/s10865-013-9510-0.
96. Hinwood, M., Tynan, R. J., Charnley, J. L., Beynon, S. B., Day, T. A., and Walker, F. R. (2012). Chronic stress induced remodeling of the prefrontal cortex: structural re-organization of microglia and the inhibitory effect of minocycline. Cereb. Cortex 24, 1058-1068. doi: 10.1093/cercor/bhs151.
97. Ho, N., Balu, D. T., Hilario, M. R., Blendy, J. A., and Lucki, I. (2012). Depressive phenotypes evoked by experimental diabetes are reversed by insulin. Physiol. Behav. 105, 702-708. doi: 10.1016/j.physbeh.2011.09.003.
98. Hoffmire, C. A., Block, R. C., Thevenet-Morrison, K., and van Wijngaarden, E. (2012). Associations between omega-3 poly-unsaturated fatty acids from fish consumption and severity of depressive symptoms: an analysis of the 2005-2008 National Health and Nutrition Examination Survey. Prostaglandins Leukotrienes Essential Fatty Acids 86, 155-160. doi: 10.1016/j.plefa.2012.03.003.
99. Holleman, M., Vreeburg, S. A., Dekker, J. J., and Penninx, B. W. (2012). The relationships of working conditions, recent stressors and childhood trauma with salivary cortisol levels. Psychoneuroendocrinology 37, 801-809. doi: 10.1016/j.psyneuen.2011.09.012.
100. Holmes, A. (2008). Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease. Neurosci. Biobehav. Rev. 32, 1293-1314. doi: 10.1016/j.neubiorev.2008.03.006.
101. Horikawa, H., Kato, T. A., Mizoguchi, Y., Monji, A., Seki, Y., Ohkuri, T., et al. (2010). Inhibitory effects of SSRIs on IFN-gamma induced microglial activation through the regulation of intracellular calcium. Prog. Neuropsychopharmacol. Biol. Psychiatry 34, 1306-1316. doi: 10.1016/j.pnpbp.2010.07.015.
102. Howren, M. B., Lamkin, D. M., and Suls, J. (2009). Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 71, 171-186. doi: 10.1097/PSY.0b013e3181907c1b.
103. Ising, M., Horstmann, S., Kloiber, S., Lucae, S., Binder, E. B., Kern, N., et al. (2007). Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression-a potential biomarker. Biol. Psychiatry 62, 47-54. doi: 10.1016/j.biopsych.2006.07.039.
104. Jabbi, M., Korf, J., Kema, I. P., Hartman, C., van der Pompe, G., Minderaa, R. B., et al. (2007). Convergent genetic modulation of the endocrine stress response involves polymorphic variations of 5-HTT, COMT and, MAOA. Mol. Psychiatry 12, 483-490. doi: 10.1038/sj.mp.4001975.
105. Jazayeri, S., Keshavarz, S. A., Tehrani-Doost, M., Djalali, M., Hosseini, M., Amini, H., et al. (2010). Effects of eicosapentaenoic acid and fluoxetine on plasma cortisol, serum interleukin-1beta and interleukin-6 concentrations in patients with major depressive disorder. Psychiatry Res. 178, 112-115. doi: 10.1016/j.psychres.2009.04.013.
106. Jokinen, J., and Nordstrom, P. (2009). HPA axis hyperactivity and cardiovascular mortality in mood disorder inpatients. J. Affect. Disord. 116, 88-92. doi: 10.1016/j.jad.2008.10.025.
107. Kannel, W. B., Kannel, C., Paffenbarger, Jr. R. S., and Cupples, L. A. (1987). Heart rate and cardiovascular mortality: the Framingham Study. Am. Heart J. 113, 1489-1494. doi: 10.1016/0002-8703(87)90666-1.
108. Karatsoreos, I. N., Bhagat, S. M., Bowles, N. P., Weil, Z. M., Pfaff, D. W., and McEwen, B. S. (2010). Endocrine and physiological changes in response to chronic corticosterone: a potential model of the metabolic syndrome in mouse. Endocrinology 151, 2117-2127. doi: 10.1210/en.2009-1436.
109. Kazakou, P., Kyriazopoulou, V., Michalaki, M., Ierodiakonou, V., Psyrogiannis, A., and Habeos, I. (2012). Activated hypothalamic pituitary adrenal axis in patients with metabolic syndrome. Horm. Metab. Res. 44, 839-844. doi: 10.1055/s-0032-1311632.
110. Keating, C., Dawood, T., Barton, D. A., Lambert, G. W., and Tilbrook, A. J. (2013). Effects of selective serotonin reuptake inhibitor treatment on plasma oxytocin and cortisol in major depressive disorder. BMC Psychiatry 13:124. doi: 10.1186/1471-244x-13-124.
111. Kendler, K. S., and Gardner, C. O. (2010). Dependent stressful life events and prior depressive episodes in the prediction of major depression: the problem of causal inference in psychiatric epidemiology. Arch. Gen. Psychiatry 67, 1120-1127. doi: 10.1001/archgenpsychiatry.2010.136.
112. Kenna, H. A., Poon, A. W., de los Angeles, C. P., and Koran, L. M. (2011). Psychiatric complications of treatment with corticosteroids: review with case report. Psychiatry Clin. Neurosci. 65, 549-560. doi: 10.1111/j.1440-1819.2011.02260.x.
113. Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., and Walters, E. E. (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62, 593-602. doi: 10.1001/archpsyc.62.6.593.
114. Kettenmann, H., Hanisch, U.-K., Noda, M., and Verkhratsky, A. (2011). Physiology of Microglia. Physiol. Rev. 91, 461-553. doi: 10.1152/physrev.00011.2010.
115. Kimbro, L. B., Steers, W. N., Mangione, C. M., Duru, O. K., and Ettner, S. L. (2012). The association of depression and the cardiovascular risk factors of blood pressure, HbA1c, and body mass index among patients with diabetes: results from the translating research into action for diabetes study. Int. J. Endocrinol. 2012, 747460. doi: 10.1155/2012/747460.
116. Knol, M. J., Twisk, J. W., Beekman, A. T., Heine, R. J., Snoek, F. J., and Pouwer, F. (2006). Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia 49, 837-845. doi: 10.1007/s00125-006-0159-x.
117. Koenig, W. (2001). Inflammation and coronary heart disease: an overview. Cardiol. Rev. 9, 31-35. doi: 10.1097/00045415-200101000-00007.
118. Krishnan, R., Cella, D., Leonardi, C., Papp, K., Gottlieb, A. B., Dunn, M., et al. (2007). Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. Br. J. Dermatol. 157, 1275-1277. doi: 10.1111/j.1365-2133.2007.08205.x.
119. Kronish, I. M., Carson, A. P., Davidson, K. W., Muntner, P., and Safford, M. M. (2012). Depressive symptoms and cardiovascular health by the american heart association's definition in the reasons for geographic and racial differences in stroke (REGARDS) study. PLoS ONE 7:e52771. doi: 10.1371/journal.pone.0052771.
120. Kumsta, R., Entringer, S., Koper, J. W., van Rossum, E. F. C., Hellhammer, D. H., and Wüst, S. (2007). Sex specific associations between common glucocorticoid receptor gene variants and hypothalamus-pituitary-adrenal axis responses to psychosocial stress. Biol. Psychiatry 62, 863-869. doi: 10.1016/j.biopsych.2007.04.013.
121. Kurina, L. M., Goldacre, M. J., Yeates, D., and Gill, L. E. (2001). Depression and anxiety in people with inflammatory bowel disease. J. Epidemiol. Commun. Health 55, 716-720. doi: 10.1136/jech.55.10.716.
122. Kurz, K., Schroecksnadel, S., Weiss, G., and Fuchs, D. (2011). Association between increased tryptophan degradation and depression in cancer patients. Curr. Opin. Clin. Nutr. Metab. Care 14, 49-56. doi: 10.1097/MCO.0b013e328340d849.
123. Kyrou, I., and Tsigos, C. (2009). Stress hormones: physiological stress and regulation of metabolism. Curr. Opin. Pharmacol. 9, 787-793. doi: 10.1016/j.coph.2009.08.007.
124. Lechin, F., van der Dijs, B., Orozco, B., Lechin, M. E., Baez, S., Lechin, A. E., et al. (1995). Plasma neurotransmitters, blood pressure, and heart rate during supine-resting, orthostasis, and moderate exercise conditions in major depressed patients. Biol. Psychiatry 38, 166-173. doi: 10.1016/0006-3223(94)00258-5.
125. Leonard, B. E. (2006). HPA and immune axes in stress: involvement of the serotonergic system. Neuroimmunomodulation 13, 268-276. doi: 10.1159/000104854.
126. Lesch, K.-P., Bengel, D., Heils, A., Sabol, S. Z., Greenberg, B. D., Petri, S., et al. (1996). Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274, 1527-1531. doi: 10.1126/science.274.5292.1527.
127. Levine, B., Kalman, J., Mayer, L., Fillit, H. M., and Packer, M. (1990). Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Eng. J. Med. 323, 236-241. doi: 10.1056/NEJM199007263230405.
128. Lin, P. Y., and Su, K. P. (2007). A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J. Clin. Psychiatry 68, 1056-1061. doi: 10.4088/JCP.v68n0712.
129. Liu, R. T., and Alloy, L. B. (2010). Stress generation in depression: a systematic review of the empirical literature and recommendations for future study. Clin. Psychol. Rev. 30, 582-593. doi: 10.1016/j.cpr.2010.04.010.
130. Lo Fermo, S., Barone, R., Patti, F., Laisa, P., Cavallaro, T. L., Nicoletti, A., et al. (2010). Outcome of psychiatric symptoms presenting at onset of multiple sclerosis: a retrospective study. Multiple Sclerosis (Houndmills, Basingstoke, England) 16, 742-748. doi: 10.1177/1352458510365157.
131. Lu, Y., Feng, L., Feng, L., Nyunt, M. S., Yap, K. B., and Ng, T. P. (2013). Systemic inflammation, depression and obstructive pulmonary function: a population-based study. Respir. Res. 14, 53. doi: 10.1186/1465-9921-14-53.
132. Ludescher, B., Najib, A., Baar, S., Machann, J., Schick, F., Buchkremer, G., et al. (2008). Increase of visceral fat and adrenal gland volume in women with depression: preliminary results of a morphometric MRI study. Int. J. Psychiatry Med. 38, 229-240. doi: 10.2190/PM.38.3.a.
133. Macfarlane, D. P., Forbes, S., and Walker, B. R. (2008). Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J. Endocrinol. 197, 189-204. doi: 10.1677/JOE-08-0054.
134. Maes, M. (1999). Major depression and activation of the inflammatory response system. Adv. Exp. Med. Biol. 461, 25-46. doi: 10.1007/978-0-585-37970-8_2.
135. Maes, M. (2012). Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and may even aggravate the pathophysiology underpinning depression. Metab. Brain Dis. 27, 405-413. doi: 10.1007/s11011-012-9326-6.
136. Maes, M., Kubera, M., Leunis, J. C., and Berk, M. (2012a). Increased IgA and IgM responses against gut commensals in chronic depression: further evidence for increased bacterial translocation or leaky gut. J. Affect. Disord. 141, 55-62. Epub 2012/03/14. doi: 10.1016/j.jad.2012.02.023.
137. Maes, M., Berk, M., Goehler, L., Song, C., Anderson, G., Galecki, P., et al. (2012b). Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med. 10:66. doi: 10.1186/1741-7015-10-66.
138. Maes, M., Kubera, M., and Leunis, J. C. (2008). The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol. Lett. 29, 117-124.
139. Maes, M., Meltzer, H. Y., Scharpe, S., Bosmans, E., Suy, E., De Meester, I., et al. (1993). Relationships between lower plasma L-tryptophan levels and immune-inflammatory variables in depression. Psychiatry Res. 49, 151-165. doi: 10.1016/0165-1781(93)90102-M.
140. Maes, M., Mihaylova, I., Kubera, M., Uytterhoeven, M., Vrydags, N., and Bosmans, E. (2009). Lower plasma Coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness. Neuro Endocrinol. Lett. 30, 462-469.
141. Mann, J. N., and Thakore, J. H. (1999). Melancholic depression and abdominal fat distribution: a mini-review. Stress 3, 1-15. doi: 10.3109/10253899909001108.
142. Manthey, L., Leeds, C., Giltay, E. J., van Veen, T., Vreeburg, S. A., Penninx, B. W., et al. (2011). Antidepressant use and salivary cortisol in depressive and anxiety disorders. Eur. Neuropsychopharmacol. 21, 691-699. doi: 10.1016/j.euroneuro.2011.03.002.
143. Margaretten, M., Barton, J., Julian, L., Katz, P., Trupin, L., Tonner, C., et al. (2011a). Socioeconomic determinants of disability and depression in patients with rheumatoid arthritis. Arthritis Care Res. 63, 240-246. doi: 10.1002/acr.20345.
144. Margaretten, M., Julian, L., Katz, P., and Yelin, E. (2011b). Depression in patients with rheumatoid arthritis: description, causes and mechanisms. Int. J. Clin. Rheumatol. 6, 617-623. doi: 10.2217/ijr.11.6.
145. Martins, J. G., Bentsen, H., and Puri, B. K. (2012). Eicosapentaenoic acid appears to be the key omega-3 fatty acid component associated with efficacy in major depressive disorder: a critique of Bloch and Hannestad and updated meta-analysis. Mol. Psychiatry 17, 1144-1149. discussion 63-67. doi: 10.1038/mp.2012.25.
146. Martocchia, A., Curto, M., Toussan, L., Stefanelli, M., and Falaschi, P. (2011). Pharmacological strategies against glucocorticoid-mediated brain damage during chronic disorders. Recent Pat. CNS Drug Discov. 6, 196-204. doi: 10.2174/157488911796958020.
147. Matthews, L. C., and Hanley, N. A. (2011). The stress of starvation: glucocorticoid restraint of beta cell development. Diabetologia 54, 223-226. doi: 10.1007/s00125-010-1963-x.
148. Mehta, D., Raison, C. L., Woolwine, B. J., Haroon, E., Binder, E. B., Miller, A. H., et al. (2013). Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression. Brain Behav. Immun. 31, 205-215. doi: 10.1016/j.bbi.2013.04.004.
149. Mendlewicz, J., Kriwin, P., Oswald, P., Souery, D., Alboni, S., and Brunello, N. (2006). Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int. Clin. Psychopharmacol. 21, 227-231. doi: 10.1097/00004850-200607000-00005.
150. Menke, A., Klengel, T., Rubel, J., Bruckl, T., Pfister, H., Lucae, S., et al. (2013). Genetic variation in FKBP5 associated with the extent of stress hormone dysregulation in major depression. Genes Brain Behav. 12, 289-296. doi: 10.1111/gbb.12026.
151. Miller, A. H., Maletic, V., and Raison, C. L. (2009). Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 65, 732-741. doi: 10.1016/j.biopsych.2008.11.029.
152. Minghetti, L. (2004). Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J. Neuropathol. Exp. Neurol. 63, 901-910.
153. Miyaoka, T., Wake, R., Furuya, M., Liaury, K., Ieda, M., Kawakami, K., et al. (2012). Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study. Prog. Neuropsychopharmacol. Biol. Psychiatry 37, 222-226. doi: 10.1016/j.pnpbp.2012.02.002.
154. Mizoguchi, K., Shoji, H., Ikeda, R., Tanaka, Y., and Tabira, T. (2008). Persistent depressive state after chronic stress in rats is accompanied by HPA axis dysregulation and reduced prefrontal dopaminergic neurotransmission. Pharmacol. Biochem. Behav. 91, 170-175. doi: 10.1016/j.pbb.2008.07.002.
155. Mo, B., Feng, N., Renner, K., and Forster, G. (2008). Restraint stress increases serotonin release in the central nucleus of the amygdala via activation of corticotropin-releasing factor receptors. Brain Res. Bull. 76, 493-498. doi: 10.1016/j.brainresbull.2008.02.011.
156. Mocking, R. J., Assies, J., Bot, M., Jansen, E. H., Schene, A. H., and Pouwer, F. (2012). Biological effects of add-on eicosapentaenoic acid supplementation in diabetes mellitus and co-morbid depression: a randomized controlled trial. PLoS ONE 7:e49431. doi: 10.1371/journal.pone.0049431.
157. Mocking, R. J., Ruhe, H. G., Assies, J., Lok, A., Koeter, M. W., Visser, I., et al. (2013). Relationship between the hypothalamic-pituitary-adrenal-axis and fatty acid metabolism in recurrent depression. Psychoneuroendocrinology. doi: 10.1016/j.psyneuen.2013.01.013.
158. Mokhtari, M., Arfken, C., and Boutros, N. (2013). The DEX/CRH test for major depression: a potentially useful diagnostic test. Psychiatry Res. 208, 131-139. doi: 10.1016/j.psychres.2012.09.032.
159. Mommersteeg, P. M., Herr, R., Pouwer, F., Holt, R. I., and Loerbroks, A. (2013). The association between diabetes and an episode of depressive symptoms in the 2002 World Health Survey: an analysis of 231, 797 individuals from 47 countries. Diabetic Med. 30:e208-214. doi: 10.1111/dme.12193.
160. Muller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Muller, B., et al. (2006). The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol. Psychiatry 11, 680-684. doi: 10.1038/sj.mp.4001805.
161. Munhoz, C. D., Lepsch, L. B., Kawamoto, E. M., Malta, M. B., Lima Lde, S., Avellar, M. C., et al. (2006). Chronic unpredictable stress exacerbates lipopolysaccharide-induced activation of nuclear factor-kappaB in the frontal cortex and hippocampus via glucocorticoid secretion. J. Neurosci. 26, 3813-3820. doi: 10.1523/JNEUROSCI.4398-05.2006.
162. Musil, R., Schwarz, M. J., Riedel, M., Dehning, S., Cerovecki, A., Spellmann, I., et al. (2011). Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression-No influence of celecoxib treatment. J. Affect. Disord. 134, 217-225. doi: 10.1016/j.jad.2011.05.047.
163. Myint, A-M., Kim, Y. K., Verkerk, R., Scharpé, S., Steinbusch, H., and Leonard, B. (2007). Kynurenine pathway in major depression: evidence of impaired neuroprotection. J. Affect. Disord. 98, 143-151. doi: 10.1016/j.jad.2006.07.013.
164. Nair, A., and Bonneau, R. H. (2006). Stress-induced elevation of glucocorticoids increases microglia proliferation through NMDA receptor activation. J. Neuroimmunol. 171, 72-85. doi: 10.1016/j.jneuroim.2005.09.012.
165. Nemeroff, C. B., and Musselman, D. L. (2000). Are platelets the link between depression and ischemic heart disease. Am. Heart J. 140(4, Supplement), S57-S62. doi: 10.1067/mhj.2000.109978.
166. Otte, C., Zhao, S., and Whooley, M. A. (2012). Statin use and risk of depression in patients with coronary heart disease: longitudinal data from the heart and soul study. J. Clin. Psychiatry 73, 610-615. doi: 10.4088/JCP.11m07038.
167. Pae, C. U., Marks, D. M., Han, C., and Patkar, A. A. (2008). Does minocycline have antidepressant effect. Biomed. Pharmacother. 62, 308-311. doi: 10.1016/j.biopha.2007.12.005.
168. Palagini, L., Mosca, M., Tani, C., Gemignani, A., Mauri, M., and Bombardieri, S. (2013). Depression and systemic lupus erythematosus: a systematic review. Lupus 22, 409-416. doi: 10.1177/0961203313477227.
169. Palatini, P., and Julius, S. (1997). Association of tachycardia with morbidity and mortality: pathophysiological considerations. J. Hum. Hypertens. 11(Suppl. 1), S19-S27.
170. Palumbo, M. L., Canzobre, M. C., Pascuan, C. G., Rios, H., Wald, M., and Genaro, A. M. (2010). Stress induced cognitive deficit is differentially modulated in BALB/c and C57Bl/6 mice: correlation with Th1/Th2 balance after stress exposure. J. Neuroimmunol. 218, 12-20. doi: 10.1016/j.jneuroim.2009.11.005.
171. Pasco, J. A., Jacka, F. N., Williams, L. J., Henry, M. J., Nicholson, G. C., Kotowicz, M. A., et al. (2010). Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression. Psychother. Psychosom. 79, 323-325. doi: 10.1159/000319530.
172. Pereira, A. M., Tiemensma, J., and Romijn, J. A. (2010). Neuropsychiatric disorders in Cushing's syndrome. Neuroendocrinology 92(Suppl. 1), 65-70. doi: 10.1159/000314317.
173. Persoons, P., Vermeire, S., Demyttenaere, K., Fischler, B., Vandenberghe, J., Van Oudenhove, L., et al. (2005). The impact of major depressive disorder on the short-and long-term outcome of Crohn's disease treatment with infliximab. Aliment. Pharmacol. Ther. 22, 101-110. doi: 10.1111/j.1365-2036.2005.02535.x.
174. Pintado, C., Revilla, E., Vizuete, M. L., Jimenez, S., Garcia-Cuervo, L., Vitorica, J., et al. (2011). Regional difference in inflammatory response to LPS-injection in the brain: role of microglia cell density. J. Neuroimmunol. 238, 44-51. doi: 10.1016/j.jneuroim.2011.06.017.
175. Piwowarska, J., Chimiak, A., Matsumoto, H., Dziklinska, A., Radziwon-Zaleska, M., Szelenberger, W., et al. (2012). Serum cortisol concentration in patients with major depression after treatment with fluoxetine. Psychiatry Res. 198, 407-411. doi: 10.1016/j.psychres.2012.01.029.
176. Pucak, M. L., and Kaplin, A. I. (2005). Unkind cytokines: current evidence for the potential role of cytokines in immune-mediated depression. Int. Rev. Psychiatry 17, 477-483. doi: 10.1080/02646830500381757.
177. Puntener, U., Booth, S., Perry, V., and Teeling, J. (2012). Long-term impact of systemic bacterial infection on the cerebral vasculature and microglia. J. Neuroinflammation 9, 146. doi: 10.1186/1742-2094-9-146.
178. Raison, C. L., Broadwell, S. D., Borisov, A. S., Manatunga, A. K., Capuron, L., Woolwine, B. J., et al. (2005). Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis, C. Brain Behav. Immun. 19, 23-27. doi: 10.1016/j.bbi.2004.05.001.
179. Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., et al. (2013). A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70, 31-41. doi: 10.1001/2013.jamapsychiatry.4.
180. Reagan, L. P., Grillo, C. A., and Piroli, G. G. (2008). The As and Ds of stress: metabolic, morphological and behavioral consequences. Eur. J. Pharmacol. 585, 64-75. doi: 10.1016/j.ejphar.2008.02.050.
181. Renoir, T., Pang, T. Y., and Hannan, A. J. (2013). Effects of environmental manipulations in genetically targeted animal models of affective disorders. Neurobiol. Dis. 57, 12-27. doi: 10.1016/j.nbd.2012.04.003.
182. Rojas, P. S., Fritsch, R., Rojas, R. A., Jara, P., and Fiedler, J. L. (2011). Serum brain-derived neurotrophic factor and glucocorticoid receptor levels in lymphocytes as markers of antidepressant response in major depressive patients: a pilot study. Psychiatry Res. 189, 239-245. doi: 10.1016/j.psychres.2011.04.032.
183. Rosmond, R. (2005). Role of stress in the pathogenesis of the metabolic syndrome. Psychoneuroendocrinology 30, 1-10. doi: 10.1016/j.psyneuen.2004.05.007.
184. Rotella, F., and Mannucci, E. (2013). Diabetes mellitus as a risk factor for depression. A meta-analysis of longitudinal studies. Diabetes Res. Clin. Pract. 99, 98-104. doi: 10.1016/j.diabres.2012.11.022.
185. Rugulies, R. (2002). Depression as a predictor for coronary heart disease: a review and meta-analysis. Am. J. Prev. Med. 23, 51-61. doi: 10.1016/S0749-379700439-7.
186. Sasaki, A., de Vega, W. C., St-Cyr, S., Pan, P., and McGowan, P. O. (2013). Perinatal high fat diet alters glucocorticoid signaling and anxiety behavior in adulthood. Neuroscience 240, 1-12. doi: 10.1016/j.neuroscience.2013.02.044.
187. Schatzberg, A. F., and Lindley, S. (2008). Glucocorticoid antagonists in neuropsychiatric [corrected] disorders. Eur. J. Pharmacol. 583, 358-364. doi: 10.1016/j.ejphar.2008.01.001.
188. Schewitz, L. P., Lee, R. W., Dayan, C. M., and Dick, A. D. (2009). Glucocorticoids and the emerging importance of T cell subsets in steroid refractory diseases. Immunopharmacol. Immunotoxicol. 31, 1-22. doi: 10.1080/08923970802334848.
189. Schmidt, H. D., Shelton, R. C., and Duman, R. S. (2011). Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology 36, 2375-2394. doi: 10.1038/npp.2011.151.
190. Seldenrijk, A., van Hout, H. P. J., van Marwijk, H. W. J., de Groot, E., Gort, J., Rustemeijer, C., et al. (2013). Sensitivity to depression or anxiety and subclinical cardiovascular disease. J. Affect. Disord. 146, 126-131. doi: 10.1016/j.jad.2012.06.026.
191. Serber, E. R., Edwards-Hampton, S. A., Yeager, B., Clair, M., Taylor, M., Galloway, S. K., et al. (2012). Prevalence of chest pain, depression, somatization, anxiety, global distress, and substance use among cardiac and pulmonary rehabilitation patients. Pain Res. Treat. 2012, 4. doi: 10.1155/2012/138680.
192. Siddiqui, R. A., and Harvey, K. A. (2013). Dietary interventions with n-3 fatty acids or probiotics targeting post-myocardial infarction depression. Br. J. Nutr. 109, 1-3. doi: 10.1017/S0007114512004254.
193. Smolderen, K. G., Spertus, J. A., Vriens, P. W., Kranendonk, S., Nooren, M., and Denollet, J. (2010). Younger women with symptomatic peripheral arterial disease are at increased risk of depressive symptoms. J. Vasc. Surg. 52, 637-644. doi: 10.1016/j.jvs.2010.04.025.
194. Soczynska, J. K., Mansur, R. B., Brietzke, E., Swardfager, W., Kennedy, S. H., Woldeyohannes, H. O., et al. (2012). Novel therapeutic targets in depression: minocycline as a candidate treatment. Behav. Brain Res. 235, 302-317. doi: 10.1016/j.bbr.2012.07.026.
195. Stafford, L., and Berk, M. (2011). The use of statins after a cardiac intervention is associated with reduced risk of subsequent depression: proof of concept for the inflammatory and oxidative hypotheses of depression. J. Clin. Psychiatry 72, 1229-1235. doi: 10.4088/JCP.09m05825blu.
196. Sternberg, E. M. (2006). Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat. Rev. Immunol. 6, 318-328. doi: 10.1038/nri1810.
197. Stetler, C., and Miller, G. E. (2011). Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom. Med. 73, 114-126. doi: 10.1097/PSY.0b013e31820ad12b.
198. Taler, M., Gil-Ad, I., Lomnitski, L., Korov, I., Baharav, E., Bar, M., et al. (2007). Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur. Neuropsychopharmacol. 17, 774-780. doi: 10.1016/j.euroneuro.2007.03.010.
199. Tatebayashi, Y., Nihonmatsu-Kikuchi, N., Hayashi, Y., Yu, X., Soma, M., and Ikeda, K. (2012). Abnormal fatty acid composition in the frontopolar cortex of patients with affective disorders. Trans. Psychiatry 2:e204. doi: 10.1038/tp.2012.132.
200. Thomson, F., and Craighead, M. (2008). Innovative approaches for the treatment of depression: targeting the HPA axis. Neurochem. Res. 33, 691-707. doi: 10.1007/s11064-007-9518-3.
201. Tonelli, L. H., Holmes, A., and Postolache, T. T. (2008). Intranasal immune challenge induces sex-dependent depressive-like behavior and cytokine expression in the brain. Neuropsychopharmacology 33, 1038-1048. doi: 10.1038/sj.npp.1301488.
202. Touma, C., Fenzl, T., Ruschel, J., Palme, R., Holsboer, F., Kimura, M., et al. (2009). Rhythmicity in mice selected for extremes in stress reactivity: behavioural, endocrine and sleep changes resembling endophenotypes of major depression. PLoS ONE 4:e4325. doi: 10.1371/journal.pone.0004325.
203. Triantafillidis, J. K., Merikas, E., and Gikas, A. (2013). Psychological factors and stress in inflammatory bowel disease. Expert Rev. Gastroenterol. Hepatol. 7, 225-238. doi: 10.1586/egh.13.4.
204. Tynan, R. J., Naicker, S., Hinwood, M., Nalivaiko, E., Buller, K. M., Pow, D. V., et al. (2010). Chronic stress alters the density and morphology of microglia in a subset of stress-responsive brain regions. Brain Behav. Immun. 24, 1058-1068. doi: 10.1016/j.bbi.2010.02.001.
205. Tyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., et al. (2006). Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367, 29-35. doi: 10.1016/S0140-6736(05)67763-X.
206. Tyrka, A. R., Walters, O. C., Price, L. H., Anderson, G. M., and Carpenter, L. L. (2012). Altered response to neuroendocrine challenge linked to indices of the metabolic syndrome in healthy adults. Horm. Metab. Res. 44, 543-549. doi: 10.1055/s-0032-1306342.
207. Udina, M., Castellvi, P., Moreno-Espana, J., Navines, R., Valdes, M., Forns, X., et al. (2012). Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J. Clin. Psychiatry 73, 1128-1138. doi: 10.4088/JCP.12r07694.
208. Valkanova, V., and Ebmeier, K. P. (2013). Vascular risk factors and depression in later life: a systematic review and meta-analysis. Biol. Psychiatry 73, 406-413. doi: 10.1016/j.biopsych.2012.10.028.
209. van Dartel, S. A. A., Fransen, J., Kievit, W., Flendrie, M., den Broeder, A. A., Visser, H., et al. (2013). Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann. Rheum. Dis. 72, 895-900. doi: 10.1136/annrheumdis-2012-201338.
210. Van der Does, A. J. (2001). The effects of tryptophan depletion on mood and psychiatric symptoms. J. Affect. Disord. 64, 107-119. doi: 10.1016/S0165-0327(00)00209-3.
211. van Holten, T. C., Waanders, L. F., de Groot, P. G., Vissers, J., Hoefer, I. E., Pasterkamp, G., et al. (2013). Circulating biomarkers for predicting cardiovascular disease risk; a systematic review and comprehensive overview of meta-analyses. PLoS ONE 8:e62080. doi: 10.1371/journal.pone.0062080.
212. van Raalte, D. H., Ouwens, D. M., and Diamant, M. (2009). Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options. Eur. J. Clin. Invest. 39, 81-93. doi: 10.1111/j.1365-2362.2008.02067.x.
213. van Reedt Dortland, A. K., Vreeburg, S. A., Giltay, E. J., Licht, C. M., Vogelzangs, N., van Veen, T., et al. (2013). The impact of stress systems and lifestyle on dyslipidemia and obesity in anxiety and depression. Psychoneuroendocrinology 38, 209-218. doi: 10.1016/j.psyneuen.2012.05.017.
214. van Rossum, E. F. C., Binder, E. B., Majer, M., Koper, J. W., Ising, M., Modell, S., et al. (2006). Polymorphisms of the glucocorticoid receptor gene and major depression. Biol. Psychiatry 59, 681-688. doi: 10.1016/j.biopsych.2006.02.007.
215. van West, D., Van Den Eede, F., Del-Favero, J., Souery, D., Norrback, K.-F., Van Duijn, C., et al. (2005). Glucocorticoid receptor gene-based snp analysis in patients with recurrent major depression. Neuropsychopharmacology 31, 620-627. doi: 10.1038/sj.npp.1300898.
216. Vignau, J., Costisella, O., Canva, V., Imbenotte, M., Duhamel, A., and Lhermitte, M. (2009). [Impact of interferon alpha immunotherapy on tryptophan metabolism in patients with chronic hepatitis, C. Results of a pilot studies on ten patients]. L'Encephale 35, 477-483. doi: 10.1016/j.encep.2007.09.007.
217. Villeda, S. A., Luo, J., Mosher, K. I., Zou, B., Britschgi, M., Bieri, G., et al. (2011). The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 477, 90-94. doi: 10.1038/nature10357.
218. Vogelzangs, N., Beekman, A. T., Dik, M. G., Bremmer, M. A., Comijs, H. C., Hoogendijk, W. J., et al. (2009). Late-life depression, cortisol, and the metabolic syndrome. Am. J. Geriatr. Psychiatry 17, 716-721. doi: 10.1097/JGP.0b013e3181aad5d7.
219. Vreeburg, S. A., Hoogendijk, W. J., van Pelt, J., Derijk, R. H., Verhagen, J. C., van Dyck, R., et al. (2009). Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large cohort study. Arch. Gen. Psychiatry 66, 617-626. doi: 10.1001/archgenpsychiatry.2009.50.
220. Vreeburg, S. A., Zitman, F. G., van Pelt, J., Derijk, R. H., Verhagen, J. C., van Dyck, R., et al. (2010). Salivary cortisol levels in persons with and without different anxiety disorders. Psychosom. Med. 72, 340-347. doi: 10.1097/PSY.0b013e3181d2f0c8.
221. Wake, H., Moorhouse, A. J., Jinno, S., Kohsaka, S., and Nabekura, J. (2009). Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J. Neurosci. 29, 3974-3980. doi: 10.1523/jneurosci.4363-08.2009.
222. Walker, A. J., Burnett, S. A., Hasebe, K., McGillivray, J. A., Gray, L. J., McGee, S. L., et al. (2013). Chronic adrenocorticotrophic hormone treatment alters tricyclic antidepressant efficacy and prefrontal monoamine tissue levels. Behav. Brain Res. 242, 76-83. doi: 10.1016/j.bbr.2012.12.033.
223. Wang, Y., Yang, F., Liu, Y. F., Gao, F., and Jiang, W. (2011). Acetylsalicylic acid as an augmentation agent in fluoxetine treatment resistant depressive rats. Neurosci. Lett. 499, 74-79. doi: 10.1016/j.neulet.2011.05.035.
224. Warrington, T. P., and Bostwick, J. M. (2006). Psychiatric adverse effects of corticosteroids. Mayo Clin. Proc. 81, 1361-1367. doi: 10.4065/81.10.1361.
225. Watanabe, S., Kanada, S., Takenaka, M., and Hamazaki, T. (2004). Dietary n-3 fatty acids selectively attenuate LPS-induced behavioral depression in mice. Physiol. Behav. 81, 605-613. doi: 10.1016/j.physbeh.2004.02.021.
226. Watson, S., Gallagher, P., Porter, R. J., Smith, M. S., Herron, L. J., Bulmer, S., et al. (2012). A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression. Biol. Psychiatry 72, 943-949. doi: 10.1016/j.biopsych.2012.05.029.
227. Wichers, M. C., Koek, G. H., Robaeys, G., Verkerk, R., Scharpe, S., and Maes, M. (2005). IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol. Psychiatry 10, 538-544. doi: 10.1038/sj.mp.4001600.
228. Wolfram, M., Bellingrath, S., Feuerhahn, N., and Kudielka, B. M. (2013). Emotional exhaustion and overcommitment to work are differentially associated with hypothalamus-pituitary-adrenal (HPA) axis responses to a low-dose ACTH1-24 (Synacthen) and dexamethasone-CRH test in healthy school teachers. Stress (Amst.) 16, 54-64. doi: 10.3109/10253890.2012.683465.
229. Young, A. H., Gallagher, P., Watson, S., Del-Estal, D., Owen, B. M., and Ferrier, I. N. (2004). Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 29, 1538-1545. doi: 10.1038/sj.npp.1300471.
230. Zalachoras, I., Houtman, R., Atucha, E., Devos, R., Tijssen, A. M., Hu, P., et al. (2013). Differential targeting of brain stress circuits with a selective glucocorticoid receptor modulator. Proc. Natl. Acad. Sci. U.S.A. 110, 7910-7915. doi: 10.1073/pnas.1219411110.
231. Zimmermann, P., Brückl, T., Nocon, A., Pfister, H., Binder, E. B., Uhr, M., et al. (2011). Interaction of FKBP5 gene variants and adverse life events in predicting depression onset: results from a 10-year prospective community study. Am. J. Psychiatry 168, 1107-1116. doi: 10.1176/appi.ajp.2011.10111577.
232. Zorrilla, E. P., Luborsky, L., McKay, J. R., Rosenthal, R., Houldin, A., Tax, A., et al. (2001). The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav. Immun. 15, 199-226. doi: 10.1006/brbi.2000.0597.
233. Zou, Y. F., Wang, F., Feng, X. L., Li, W. F., Tao, J. H., Pan, F. M., et al. (2010). Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders. Neurosci. Lett. 484, 56-61. doi: 10.1016/j.neulet.2010.08.019.